Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Kim, EJ; Kim, YH; Rook, AH; Lerner, A; Duvic, M; Reddy, S; Robak, T; Becker, JC; Samtsov, A; McCulloch, W; Waksman, J; Whittaker, S.
Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma.
Leuk Lymphoma. 2015; 56(10):2847-2854 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Becker Jürgen Christian
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
Cutaneous T-cell lymphoma (CTCL) is a rare heterogeneous group of non-Hodgkin lymphomas that arises in the skin but can progress to systemic disease (lymph nodes, blood, viscera). Historically, in clinical trials of CTCL there has been little consistency in how responses were defined in each disease "compartment"; some studies only assessed responses in the skin. The histone deacetylase inhibitor romidepsin is approved by the US Food and Drug Administration for the treatment of CTCL in patients who have received at least one prior systemic therapy. Phase II studies that led to approval used rigorous composite end points that incorporated disease assessments in all compartments. The objective of this analysis was to thoroughly examine the activity of romidepsin within each disease compartment in patients with CTCL. Romidepsin was shown to have clinical activity across disease compartments and is suitable for use in patients with CTCL having skin involvement only, erythroderma, lymphadenopathy and/or blood involvement.
Find related publications in this database (using NLM MeSH Indexing)
Antibiotics, Antineoplastic - pharmacology
Antibiotics, Antineoplastic - therapeutic use
Depsipeptides - pharmacology
Depsipeptides - therapeutic use
Female -
Humans -
Lymphoma, T-Cell, Cutaneous - drug therapy
Lymphoma, T-Cell, Cutaneous - pathology
Male -
Neoplasm Grading -
Neoplasm Staging -
Retreatment -
Treatment Outcome -
Tumor Burden -

Find related publications in this database (Keywords)
Lymphoma and Hodgkin disease
pharmacotherapeutics
prognostication
© Meduni Graz Impressum